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Abstract 
Purpose: To evaluate an interleaved MRI sampling strategy that acquires both high temporal 
resolution (HTR) dynamic contrast-enhanced (DCE) data for quantifying breast tumor blood 
flow (TBF) and high spatial resolution (HSR) DCE data for clinical reporting, following a 
single standard injection of contrast agent. 
Methods: A simulation study was used to evaluate the performance of the interleaved 
technique under different conditions. In a prospective clinical study, eighteen patients with 
primary breast cancer due to undergo NACT, were examined using interleaved HTR and 
HSR DCE-MRI at 1.5T. Tumor regions of interest (ROI) were analyzed with a two-
compartment tracer kinetic model. Paired parameters (n=10) from data acquired before and 
post-cycle 2 of NACT were compared using the nonparametric Wilcoxon signed-rank test.  
Results: Simulations demonstrated that TBF was reliably estimated using the proposed 
strategy. ROI analysis revealed significant changes in TBF (0.81 to 0.43 ml/min/ml; 
P=0.002) following 2 cycles of NACT. HSR data were reported in the normal way and 
enabled the assessment of tumor volume, which decreased by 53% following NACT 
(P=0.065). 
Conclusion: TBF can be measured reliably using the proposed strategy without 
compromising a standard clinical protocol. Furthermore, in our feasibility study TBF 
decreased significantly following NACT whereas capillary permeability surface-area product 
did not.  
Key Words: DCE-MRI; tracer kinetic model; breast; tumor blood flow; chemotherapy; high 
temporal resolution;  
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Introduction  
Breast cancer is the most common cancer in women worldwide. Survival rates for women 
who are diagnosed early have improved, but this is not the case with late stage disease (1). 
Patients with advanced breast cancer often undergo neoadjuvant chemotherapy (NACT), with 
the aim of reducing tumor size. Nevertheless a significant proportion of patients do not 
benefit from the treatment (2), but still suffer from its side effects (3,4). It is important to 
identify these patients at an early stage of treatment and, where possible, change their 
therapy.  
Treatment response is currently assessed by a combination of clinical examination and 
imaging techniques such as mammography, ultrasound and MRI. However, these techniques 
are typically limited to evaluating morphological changes, such as tumor diameter (5) and 
volume (6). It is recognized that changes in physiology, such as tumor blood flow (TBF), 
precede morphological changes and this allows an assessment of treatment response at an 
earlier stage of therapy (7,8). Since 1990 several studies have demonstrated that it is possible 
to estimate physiological processes using dynamic contrast enhanced (DCE)-MRI and many 
studies have exploited this approach to monitor NACT response, either by semi-quantitative 
signal-time curve characterization or by measurement and modeling of tumor contrast uptake 
(9-13).  
Despite the promise of DCE-MRI to monitor treatment response, there has been limited 
adoption of quantitative MRI techniques into clinical practice. Accurate modeling of tracer 
kinetic time series requires the use of imaging protocols with high temporal resolution (HTR) 
and such data are usually acquired at the expense of high spatial resolution (HSR) (14). The 
American College of Radiology guidelines recommend the acquisition of HSR data: a slice 
thickness of less than 3 mm with in-plane spatial resolution of 1 mm (or less), suggesting that 
a temporal resolution of less than 4 minutes will suffice for ³accurate capture of lesion 
kinetics´ (http://www.acr.org/Quality-Safety/Standards-Guidelines). In the case of TBF 
measurement however, the sampling interval plays a major role with the necessity of 
acquiring data in both the breasts and a feeding artery (15-17). A sampling rate of 1 imaging 
volume every 2 or 3 s is needed to capture the temporal characteristics of the arterial input 
function (AIF) during the early passes of the contrast agent bolus though this sampling rate 
can be relaxed later in the time-course (16,17).  
Some studies simply neglect HSR images or breast coverage to improve the sampling rate 
(14,18,19) while others have proposed different approaches to meet these conflicting 
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requirements. A two-bolus technique was proposed to allow for separate HSR and HTR 
imaging however it significantly increases scanning time and reduces the contrast dose that 
can be used in each bolus (20). Song et al demonstrated a technique that allows acquisition of 
HTR images (12-15 s) while simultaneously allowing the reconstruction of HSR images from 
the same datasets (21). Saranathan et al proposed an acquisition technique that switched 
between HTR with moderate spatial resolution (9 s; 1.1×2.5×4 mm) during the contrast agent 
wash-in phase and low temporal resolution but HSR (120 s; 1.1×1×1.2 mm) during the wash-
out phase (22). Despite these proposals, acquisition rates for estimation of TBF remain 
suboptimal (16,17). 
An alternative approach to that of Saranathan et al. is to acquire HSR and HTR images in an 
interleaved manner. The use of a dual-echo multi-slice acquisition by Grovik et al (23) 
hampered measurement of the AIF but enabled DCE-MRI at HTR while retaining HSR 
images for clinical use. The purpose of this study is to evaluate the feasibility of quantifying 
tumor blood flow (TBF) in patients with advanced breast cancer undergoing neoadjuvant 
chemotherapy (NACT), using an interleaved dynamic contrast-enhanced (DCE) MR imaging 
technique. 
Methods  
Tracer kinetic model and sampling requirements  
A two-compartment exchange model (2CXM) describes the transport of contrast agent 
through a tumor in terms of TBF (Fb), capillary permeability surface-area product (PS), blood 
volume fraction (vb) and extracellular extravascular space (EES) volume fraction (ve). The 
following time-domain solution was used for analysis of the signal-time data: ܥሺݐሻ ൌ ܨ௕ሺ⁡? െ ܪܿݐሻ ⁡? ܥ௣ሺݐሻ ٔ ሾܣ ⁡? ݁ିఈ௧ ൅ ሺ⁡? െ ܣሻ ⁡? ݁ିఉ௧ሿ            [1] 
where, Cp(t) is the AIF, the blood plasma concentration of contrast agent, C(t) is the 
concentration in the tumor and ٔ is the convolution symbol (15,24). The fit parameters (Fb, 
$Į and ȕ) can be used to derive the required tracer kinetic parameters as follows ݒ௕ ൌ ܨ௕Ȁሺܣ ⁡?ሺߙ െ ߚሻ ൅ ߚሻ ,      ܲܵ ൌ ሺ⁡? െ ܪܿݐሻ ⁡? ሾݒ௕ሺߙ ൅ ߚ െ ߙߚݒ௕Ȁܨ௕ሻ െ ܨ௕ሿ, 
   ݒ௘ ൌ ܲܵǤ ܨ௕Ȁሺߙߚݒ௕ሻ ,     ܧ ൌ ܲܵȀሾܲܵ ൅ ܨ௕ ⁡? ሺ⁡? െ ܪܿݐሻ], 
    ܭ௧௥௔௡௦ ൌ ܧ ⁡? ܨ௕ ⁡? ሺ⁡? െ ܪܿݐሻ                       [2] 
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where Hct is the large vessel hematocrit, E
 
is the extraction fraction and Ktrans is the volume 
transfer constant.
 
Quantitative analysis requires a signal from the tumor and the lumen of a 
feeding artery (the AIF). The proposed interleaved imaging scheme (Fig. 1) starts by 
acquiring a HSR volume that serves as a baseline reference for clinical reporting. During 
contrast agent administration, the acquisition scheme continues with HTR sampling to 
capture the rapid changes of the AIF and tissue curve during the early bolus passes. The 
acquisition then alternates between HSR and HTR for a further 6 minutes.  
Simulations  
In order to evaluate the performance of the interleaved strategy, a simulation study was 
undertaken. A realistic AIF (25) was simulated at HTR (0.1 s) and convolved with the tissue 
model given in Eq. 1 (using model and acquisition parameters presented in Table 1) to 
generate 3 typical tumor curve types ± 3, 4 & 5 (26).  
The HTR relative signal intensity (RSI) time curves generated were regridded to match the 
temporal resolution of our proposed MR technique (2.2 s). Tumor curves and the AIF were 
further processed to include random Gaussian noise at four different signal-to-noise ratios 
(SNR) of 20, 30, 50 and 80. SNR was defined as the maximum signal intensity in the time 
series divided by the standard deviation of the baseline signal (27,28). 1000 tissue curves 
were generated for each of the tumor curve types at each SNR level. 
The time series were cropped to simulate three sampling strategies (see Fig. 1); method 1- 
continuous HTR imaging for approximately 8 minutes, method 2 - as method 1 with gaps for 
HSR imaging as in the clinical protocol and method 3 - as method 2 with the initial burst of 
HTR data shortened (method 2: 36 volumes, method 3: 21 volumes) to remove the second 
pass of the AIF and simulate a protocol which allows earlier HSR acquisition.   
Patients  
Eighteen female patients (mean age, 48.7 years) who had locally advanced breast cancer, due 
to undergo NACT and have been referred for an MRI scan for treatment assessment, were 
eligible to this prospective study and imaged at least twice during their course of NACT. The 
study was approved by a research ethics committee and written informed consent was 
obtained. Blood samples from each patient were used to estimate the large vessel Hct before 
each MRI scan. Patients with contraindications to MRI were excluded from the study. Table 
2 shows the histological and molecular markers acquired from core sample biopsies obtained 
at baseline and the subsequent NACT regimen for each patient. 
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MR imaging  
All patients were scanned on a 1.5 T Avanto MR scanner (Siemens, Erlangen, Germany), 
positioned head first prone, using a bilateral breast coil for signal reception. To enhance 
signal from the descending aorta (which was used for the AIF (14) as there is no local artery 
of sufficient diameter that can be reliably measured in the imaging volume) a flexible matrix 
coil was also positioned on the patients' back.  
The clinical protocol began with a T1-weighted 3D spoiled gradient echo (FLASH) and a T2-
weighted turbo spin echo (TSE) sequence each in the transverse plane covering both breasts. 
Following this, axial images (FOV: 340×340×150 mm, reconstruction matrix: 128×128×30) 
were acquired using a 3D inversion recovery (IR) prepared balanced steady state free 
precession sequence (TrueFISP) at four inversion times (TI: 400, 680, 1200 and 2000 ms) to 
measure the baseline T1 relaxation times of blood and tumor (IR-TR: 3000 ms, TR/TE: 
2.7/1.3 ms, FA: 70°, GRAPPA parallel factor: 2, Tacq: 1 min per volume). 
For HTR and HSR DCE-MRI, standard vendor-supplied 3D FLASH sequences were 
employed. No modification was made to the HSR DCE-MRI images used in our institution 
for clinical reporting. These were preset to run in an interleaved manner as illustrated in Fig. 
1. The system was setup to traverse through the sequences in an automated mode, without re-
shimming or re-tuning procedures in-between. For the HTR imaging the same geometry as 
the T1 mapping was used (TR/TE: 2.7/0.8 ms, FA: 21°, GRAPPA factor 2, Tacq = 2.2 s). For 
the HSR images a 3D fat-suppressed FLASH sequence was used to generate axial images 
(TR/TE: 4.1/1.2 ms, FA: 10°, FOV: 340×340×146 mm, reconstruction matrix size: 
384×384×104, GRAPPA factor: 2, Tacq = 34 s). A dose of 0.1 mmol/kg Gd-DOTA (Dotarem, 
Guerbet Laboratories, Aulnays Sous Bois, France) was administered at 3 ml/s followed by 20 
ml saline at the start of HTR imaging. The total acquisition time of the dynamic data was 
approximately 8 minutes during which 84 HTR volumes and 8 HSR volumes were acquired. 
Postprocessing  
All MRI data were processed using PMI (Platform for Research in Medical Imaging, version 
0.4 (29)) and Matlab (Mathworks, Nattick, MA, USA). The IR images were used to obtain 
baseline T1,0 relaxation time maps by fitting Eq. 2 to the signal intensity data using a non-
linear least-squares optimization algorithm, on a voxel-by-voxel basis ܵ ൌ ܵ଴൫⁡? െ ⁡? ⁡? ݁ି்ூȀ భ்ǡబ൯     [3] 
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where S0 is the steady state signal. PMI was used to draw ROIs in the descending aorta and 
tumor in order to obtain the AIF and the corresponding tumor curve. For AIF selection, ROIs 
that covered several slices within the 3D volume of HTR data for each patient were first 
created. The 3D ROIs were then trimmed to include only voxels that had a maximum RSI 
value between 50 and 95% of all RSI maxima (chosen empirically). A 2nd criterion for AIF 
selection was that voxels were only included if the corresponding T1,0 estimates were within 
1.1 and 1.7 s. These steps were followed to minimize potential errors in the AIF such as 
partial volume, inflow or motion artifacts. The median number of voxels included in the AIF 
ROI was 426 (range 105 ± 576).  
Tumor 3D ROIs were selected on both HSR and HTR images. For the HSR data, a 
radiologist examined all MRI datasets (T1 and T2-weighted volumes as well as the 
postcontrast dynamic data) and delineated the tumor. Both enhancing and non-enhancing 
areas within the tumor were selected and these ROIs were used for tumor volume estimation. 
The 3D ROIs for the HTR images only included regions that exhibited contrast enhancement. 
The RSI data were converted to longitudinal relaxation rate changes (ǻ51) using the mean 
precontrast T1,0 estimate and the signal intensity obtained with a FLASH sequence (Eq. 3) ܵ ൌ ܵ଴ ⁡? ቀ ଵି௘ష೅ೃȀ೅భଵିୡ୭ୱሺி஺ሻ⁡?௘ష೅ೃȀ೅భቁ ⁡? ሺܨܣሻ ⁡? ݁ି் ாȀ మ்כ   [4] 
where S0 is proportional to the proton density and given the short TE used, the term ሺെȀଶכሻ was assumed to remain unchanged at a value of 1 throughout. The resulting 
time series were subsequently used for tracer kinetic modeling. The model was initially fitted 
with five parameters, the four parameters defined in Eq. 1 and bolus arrival time (BAT) that 
accounts for the delay between arrival of the contrast at the aorta and the tumor. A second fit 
was performed with BAT fixed at its best-fit value. The analysis was performed in Matlab 
using a constrained non-linear least-squares optimization algorithm (Fb, A, Į and ȕ were 
constrained to be positive and A<1). To fill the gaps in the AIF left by the acquisition of HSR 
data, interpolation was achieved using a best-fit decaying bi-exponential function (30). The 
analysis was performed blinded to any clinical results. 
To compare T1,0, tumor volume and tracer kinetic parameter estimates before and following 
treatment (for paired data only, n=10), a non-parametric Wilcoxon signed rank test was used, 
since the parameter estimates were not normally distributed (Shapiro-Wilk test, p>0.05). In 
addition, SSHDUPDQ¶VUDQNFRUUHODWLRQFRHIILFLHQWZDVXVHGWRDVVHVVWKHUHODWLRQVKLSEHWZHHQ
8 
 
parameters (for paired data only). For the analysis of the simulated data, percentage error was 
calculated for each parameter ܲ݁ݎܿ݁݊ݐܽ݃݁ܧݎݎ݋ݎ ൌ  ௫ି௫೟ೝೠ೐௫೟ೝೠ೐ ൈ ⁡?⁡?⁡?⁡?   [4] 
where ݔ and ݔ௧௥௨௘ are the estimated and the simulated value of the parameter. 
Results  
Simulations  
Simulated data for all three curve types at four SNR levels were fitted and parameter 
estimates were generated. Due to the large quantity of data generated in the simulations (3 
curve types, 4 SNR levels and 4 estimated parameters per fit), we only present the results for 
a SNR of 50 (Fig. 2), which is closest to the mean SNR calculated from the subsequent MRI 
experiments.  
The most reliable parameter estimate was Fb. Fig. 2 demonstrates that all three sampling 
strategies generate similar median estimates for Fb. However, interquartile range (IQR) in Fb 
estimates was narrowest for method 1, wider for method 2 and widest for method 3. 
Furthermore, IQR of Fb estimates for all sampling strategies becomes larger as the curve type 
changed from type 3 to type 5. Similar effects were observed for both PS and vb estimates. In 
contrast, ve estimates showed a larger IQR for type 3 and 5 curves compared to type 4. The 
results for the remaining SNR levels followed similar trends, but the IQR of the parameter 
estimates increased as SNR decreased. 
Scatter plots for combinations of parameter estimates (Figs. 3&4) illustrate that some fit 
errors occurred with type 3 and 5 curves. In general, these failures become more frequent as 
SNR decreased and as the number of data points used to fit the data decreased. Fig. 3 
demonstrates the low precision in ve estimates for type 3 curves at a SNR of 20, and how this 
improved at a SNR of 50 and as more data points were used in the fitting process (i.e. 
methods 1 and 2 outperform method 3).  
Fig. 4 (bottom row) shows that fitting a type 5 curve acquired with sampling method 3 and, to 
a lesser extent, with method 2, leads to fit failures. In particular, 2% and 27% of the fits 
generate a PS estimate close to 0 for method 2 and method 3, respectively and the number of 
fits failures increased as SNR decreased. The inability to estimate PS from these data leads to 
arbitrary ve estimates, an overestimation of vb and an underestimation of Fb. The 
corresponding scatter plots for type 4 curves (Fig.4, top row) indicate that the distribution of 
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the parameter estimates is more homogeneous, without fit errors and with the parameter 
estimates confined to a narrower range.  
Clinical application  
In this cross-sectional feasibility study we analyzed 25 MRI data sets from 15 of the 18 
patients recruited; those 15 had baseline MRI scans and 10 of them went on to have MRI 
scans following 2 cycles of EC. Three patients have missed their baseline scan due to a lack 
of scanner availability at the time and were excluded from the study. Five patients missed 
their post-cycle 2 MRI scan due to technical failures or variations in oncology requests for 
MRI. At surgery following the completion of NACT, 3 of these 10 patients (patient no. 1, 3 
and 14) showed a complete pathological response and 7 showed evidence of partial 
pathological response. 
Examples of the HSR and HTR images acquired are shown in Figs. 5 and 6, along with the 
corresponding signal-time curves. Example model fits for patients at baseline and post-cycle 
2 are illustrated in Fig. 7. Median values and ranges of the resulting parameter estimates are 
shown in Table 3. There was a significant change between baseline and post-cycle 2 in Fb, 
BAT and Ktrans estimates at the 95% confidence level (P = 0.002, 0.020 and 0.037, 
respectively). There were no significant changes in the remaining parameters. Tumor volume, 
determined from the HSR data, decreased by 53% following 2 cycles of NACT but this 
change was not significant at the 95% confidence level (P = 0.065).  
Ktrans (calculated as E⁡?Fb⁡?(1-Hct)) correlated better with PS (ȡ = 0.94, p<0.001) than with Fb 
(ȡ = 0.69, P = 0.011) and shows a borderline significant change in response to treatment 
compared to Fb. Conversely if, as is common, a one compartment model (1CM) is used to 
estimate Ktrans  (though an F-test suggests that the 2CXM model is preferred14; data not 
shown), it correlates strongly with Fb (ȡ = 0.94, P<0.001), weakly with PS (ȡ = 0.47, P = 
0.037) and shows a more significant reduction following NACT (32%, P = 0.010).  
Discussion  
In this study, we have evaluated the performance of the interleaved acquisition strategy 
introduced in Fig. 1. The protocol was compared to a conventional HTR protocol in the 
absence of interleaving through simulations and clinical feasibility was subsequently tested 
through application in patients undergoing NACT.  
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Simulations  
The performance of the proposed interleaved strategy (sampling method 2) was comparable 
to method 1 (HTR without gaps). The IQR of the parameter estimates varied with curve type 
but improved as SNR increased. Fb was the parameter that could be estimated with the 
highest accuracy and precision, irrespective of curve type or SNR.  
Simulations using sampling method 1 revealed the sources of error expected when a 
continuous HTR series is acquired. For type 3 curves, all parameter estimates (except ve) are 
confined to a narrow range. When PS is low (type 3) there is slow contrast agent 
extravasation and the curve continues to rise. The overall acquisition time is suboptimal for 
this curve type with insufficient time for contrast agent to fill the EES. This leads to 
difficulties in estimating ve and an uptake model may be more appropriate (15). Nevertheless, 
the accuracy and precision of ve estimates improves as SNR increases (Fig. 3). 
The performance of the proposed interleaved acquisition strategy (method 2) was comparable 
to method 1 in most cases. Similar characteristics were observed for type 3 curves, but ve 
estimates were more variable. The main difference between the two methods was observed in 
fitting type 5 curves. Here extravasation (PS) is high, and makes it difficult to differentiate 
contrast agent in the vascular and EES compartments. This may lead to imprecise PS, ve and 
vb estimates, worsening as the SNR and number of points used to sample the time series 
decrease. In the limit PSĺ, the model collapses to a 1CM, where the estimate of blood 
plasma volume fraction (vp) is equal to ve + vp, and ve no longer has an impact on the curve 
and can take any value as seen in ~2% of the fits at SNR 50. The number of fit errors reduces 
as the SNR increases. 
Sampling method 3 was evaluated through simulations in order to examine the importance of 
acquiring all rapid temporal changes of the AIF during the first minutes of dynamic 
acquisition. The results of the simulation suggest that reducing the number of data points can 
have a significant impact on the parameter estimates. Method 3 generated a higher number of 
imprecise ve estimates in the case of type 3 curves. Moreover the percentage of fits that result 
in fit failure in type 5 curves was appreciably higher (27% of fits for an SNR of 50, 
increasing as SNR decreases). 
Based on the simulations we concluded that the proposed interleaved acquisition scheme was 
able to generate sufficiently reliable parameter estimates compared to those obtained with a 
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conventional HTR protocol. It appears to be important to sample all the early signal changes 
in the AIF. 
Clinical application  
The acquisition technique proposed offers the potential to derive separate estimates for TBF 
and PS, and at the same time maintain the acquisition of HSR data necessary for clinical 
reporting. Since the basic structure of the routine protocol was maintained (other than a 
delayed acquisition of the first post-contrast HSR volume), our radiologists were able to 
follow the normal breast MRI reporting system (31). Figs. 5 and 6 show examples of type 5 
and type 4 curves with data from the HSR images which match the kinetic curve type derived 
from the HTR images.  
Our estimates of baseline tumor and blood T1 using the inversion recovery sequence are in 
the range of previous results (19,32-34). To our knowledge, only Brix et al. previously 
provided Fb estimates for breast tumors using DCE-MRI techniques and these compare well 
with our Fb estimates for untreated tumors (regional blood flow: ~0.61±0.25 ml/min/ml (14)). 
There is also good agreement between vb estimates (0.25±0.10), whereas ve reported by Brix 
(0.34±0.16) is somewhat higher than our median estimate. In other studies using PET and O-
15 labeled water, whole tumor mean Fb estimates in breast tumors range from 30-60 
ml/min/100 g (8,35-37) but may be systematically underestimated due to limitations in 
spatio-temporal resolution.  
We measured a significant reduction (47%, P = 0.002) in median Fb following 2 cycles of 
NACT (n=10). A similar reduction following NACT was also reported using PET imaging by 
Mankoff et al7. Ktrans has been used in previous MRI studies to monitor treatment response 
but this parameter is often measured in different ways and misinterpreted (38). The 
physiological interpretation of Ktrans reflects a combination of TBF and PS (15). However the 
contribution of each process, and hence the sensitivity of the analysis is likely to be 
dependent on model selection. These findings in conjunction with our simulations suggest 
that Fb is a good choice for measuring treatment induced changes. 
Limitations  
Although 18 patients were initially recruited only 10 had both baseline and post-cycle 2 MRI 
scans. Within the study cohort patients were treated with a variety of NACT regimens and 
this complicates any attempt to derive a correlation between TBF change and pathological 
response.  
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Although the first segment of HTR data was prolonged in order to capture the rapid temporal 
changes in the blood concentration of contrast agent during the first minutes following 
administration, there were examples of AIF time series with visible first, second and third 
passes before the acquisition switched. This should have minimal effect on Fb estimates, but 
may, in some cases, have an impact on PS and vb estimates. Furthermore, a better sampling 
strategy for the HTR images could further improve the accuracy and precision of parameter 
estimates in general. Additional simulations (data not shown) demonstrated that more 
frequent but shorter sampling intervals could improve these metrics. 
It is important to note that a 2CXM is a gross-simplification of the true distribution of 
contrast media in breast cancers. For example a study has shown that contrast media 
accumulate within the ducts, 2 minutes post-contrast administration (39). Nevertheless, the 
application of complex models is not always the best approach since this depends on several 
requirements such as noise in the time series, temporal sampling rate, accuracy of AIF 
measurement (40). In this study the data did not support a model with more than 4 
parameters. 
Conclusions 
To our knowledge this is the first study that presents an acquisition strategy to acquire both 
HSR images for clinical reporting and HTR images for quantitative DCE-MRI, with the 
ability to derive separate estimates of TBF and PS. The interleaved approach was evaluated 
using simulation studies and tested through application in patients undergoing NACT. These 
techniques will allow radiologists to adapt similar protocol strategies without significantly 
compromising the data used for clinical reporting and encourage other investigators to 
examine the physiological characteristics of tumors and their associated changes during 
treatment.   
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Tables: 
Table 1: Parameters used in Simulations 
Tracer Kinetic Model Parameters Physiological Parameters 
Tumor 
Curve 
Fb 
(ml/min/ml) 
PS 
(ml/min/ml) 
ve 
(ml/ml) 
vb 
(ml/ml) 
Blood 
T1,0 (ms) 
Tumor 
T1,0 (ms) Hct 
Type 3 0.17 0.03 0.35 0.09 
1400 1000 0.42 Type 4 0.43 0.08 0.25 0.26 
Type 5 0.86 0.15 0.15 0.43 
T1,0: Precontrast longitudinal relaxation time, Hct: Hematocrit 
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Table 2: Patient Histological Data and chemotherapy regime 
Patient 
No. Age 
Lymph 
nodes Tumor Type Grade ER status PR status 
HER 2 
Status 
NACT 
Regime 
1 58 - 
 Ductal NST 2,3 - - + 4×EC + 4×DC 
3 40 + 
 Ductal NST 2 + - + 2×EC + 4×DC 
4 47 - 
 Ductal NST 2 + + + 6×EC  
5 40 + 
 Ductal NST 2 + + - 4×EC + 2×DC 
6 49 + 
 Ductal/Lobular 1 + + - 2×EC + 6×DC 
7 50 - 
 Ductal NST 3 - - - 4×EC + 4×DC 
8 42 + 
 Ductal NST 2 + + - 3×DC + 3×FEC 
9 47 + 
 Ductal NST 3 + - - 3×DC  
10 50 - 
 Ductal NST 2 + + - 3×EC + 4×DC 
11 61 + 
 Ductal NST 3 + - + 4×EC + 4×DC 
12 42 + 
 Ductal NST 2 + + - 4×EC + 4×DC 
13 45 + 
 Ductal NST 3 - - - 4×EC + 4×DC 
14 54 + 
 Ductal NST 3 - - + 4×EC + 3×DC 
15 61 + 
 Ductal NST 3 - - - 4×EC + 4×DC 
16 60 + Basal Features 3 - - - 4×EC + 4×DC 
17 38 + 
 Ductal NST 2 + - + 2×EC + 4×DC 
18 53 + 
 Ductal NST 2,3 + - - 3×EC + 4×DC 
20 40 + 
 Ductal NST 3 + - - 4×EC + 2×DC 
Ductal NST: ductal carcinoma of no specific type, ER: estrogen receptor, PR: progesterone receptor, HER 2: human epidermal 
growth factor receptor 2, EC: epirubicin & cyclophosphamide, DC: docetaxel & cisplatin, FEC: fluorouracil & EC. 
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Table 3: Values of Estimated Parameters  
  
  Paired Data 
Parameters Baseline MRI (n=15) Baseline MRI (n=10) Post-Cycle 2 MRI (n=10) p-value 
  Median (range) Median (range) Median (range)   
Volume (ml) 13.67 (0.61 - 108.37) 16.33 (2.32 - 108.37) 7.69 (0.19 - 68.47) 0.065 
Tumor T1 (ms) 1074 (948 - 1196) 1070 (948 - 1196) 1113 (962 - 1273) 0.432 
Blood T1 (ms) 1335 (1241 - 1489) 1324 (1241 - 1489) 1384 (1317 - 1560) 0.053 
Hct 0.40 (0.35 ± 0.46) 0.40 (0.37 ± 0.46) 0.40 (0.28 - 0.47) 0.625 
BAT (s) 3.60 (1.80 - 9.60) 3.60 (1.80 - 5.40) 4.80 (3.00 - 8.14) 0.020a 
Fb (ml/min/ml) 0.68 (0.16 - 1.36) 0.81 (0.34 - 1.36) 0.43 (0.19 - 0.84) 0.002a 
PS (ml/min/ml) 0.08 (0.01 - 0.37) 0.10 (0.05 - 0.37) 0.08 (0.05 - 0.15) 0.106 
ve (ml/ml) 0.22 (0.09 - 0.39) 0.26 (0.16 - 0.39) 0.25 (0.14 - 0.33) 0.625 
vb (ml/ml) 0.25 (0.01 - 0.59) 0.24 (0.04 - 0.49) 0.23 (0.07 - 0.45) 0.695 
E (no units) 0.19 (0.02 - 0.44) 0.19 (0.11 - 0.44) 0.25 (0.11 - 0.46) 0.322 
Ktrans (/min) 0.06 (0.01 - 0.25) 0.09 (0.04 - 0.25) 0.06 (0.04 - 0.10) 0.037a 
aA difference, at 95% significance level, using a non-parametric Wilcoxon signed rank test. 
Median parameter estimates (range) for the tracer kinetic model, tumor volume and T1 for tumor and blood ROIs. A 
non-parametric Wilcoxon signed rank test was used to compare the baseline and post-cycle 2 parameter estimates 
who attended both MRI sessions (paired data). Hct =  Haematocrit, BAT = bolus arrival time, Fb = tumor blood flow, 
PS = permeability surface-area product, ve =  interstitial volume fraction, vb =  blood volume fraction, E = extraction 
fraction, Ktrans =  volume transfer constant. 
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Figures 
 
Figure 1: Schematic of the interleaved acquisition with example simulated AIF and three 
tumor curve types. The solid lines represent the simulated time series (without gaps or noise) 
and the marker points illustrate the data acquired with the interleaved technique (with noise). 
Red and blue segments represent high spatial resolution (HSR) and high temporal resolution 
(HTR) acquisitions, respectively. At the first burst of HTR imaging (segment A) 36 volumes 
were acquired for method 2, to encompass the first two passes of the contrast agent bolus. For 
method 3, this was reduced to 21 volumes (acquisition stops at the dotted line) to exclude the 
2nd pass of the AIF. During the following bursts (segments B, C and D) 16 time points were 
acquired, each segment occupying the acquisition time of a single HSR volume. There were 
eight HSR volumes acquired in total.  
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Figure 2: Box and whisker plots of the simulation results for a signal to noise ratio (SNR) 50. 
Each parameter plot groups the results by curve type (3, 4 and 5) and sampling strategy, 
method 1 (green), method 2 (red) and method 3 (black). Note the variation in y-axis scale. 
The box represents the middle 50% of values for the group (inter-quartile range) and the 
upper and lower whiskers represent the complete range beyond the middle 50%. 
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Figure 3: Scatter plots of combinations of parameter estimates from the simulation of type 3 
tumor curves and a signal to noise ratio (SNR) of 20 (top row) and 50 (bottom row). The 
middle panel (ve vs PS plot) demonstrates that the optimization process generates imprecise ve 
estimates, particularly for method 3 (grey circles). However, as the SNR increases the 
precision increases. Note that Fb, PS and vb are estimated with a higher accuracy and 
precision than ve. The white cross indicates the ground truth of the parameters. 
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Figure 4: Scatter plots of combinations of parameter estimates from the simulation of type 4 
(top row) and type 5 tumor curves (bottom row) and a signal to noise ratio (SNR) of 50. The 
simulation results indicate that the performance of the optimization process is excellent for 
the type 4 curves for all methods. On the other hand, for type 5 curves PS estimates are 
imprecise and using method 3 (grey circles), the tracer kinetic model sometimes breaks down 
and returns PS estimates close to zero. This causes an overestimation of vb, underestimation 
of Fb and a wide range of ve estimates. The white cross indicates the ground truth of the 
parameters. 
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Figure 5: High temporal resolution (HTR) 3D FLASH MR image during the first segment of 
HTR acquisitions in patient 12 (post-contrast), with the corresponding signal intensity time 
series from the tumor in the left breast. In the right column, high spatial resolution (HSR) 3D 
FLASH image acquired shortly after contrast agent administration with the respective signal 
time series.  This figure illustrates the ability of the interleaved technique to preserve HSR 
images that can be used for clinical reporting. The tumor was reported as an abnormally 
enhancing 27 mm mass exhibiting a type 5 curve with 150% enhancement.   
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Figure 6: High temporal resolution (HTR) 3D FLASH MR image during the first segment of 
HTR acquisitions in patient 3 (post-contrast), with the corresponding signal intensity time 
series from the tumor in the left breast. In the right column, high spatial resolution (HSR) 3D 
FLASH image acquired shortly after contrast agent administration with the respective signal 
time series. The time series generated from both the HSR and HTR images indicate a type 4 
tumor curve. Also note that low enhancement areas within tumor can be identified on both 
HSR and HTR images. This tumor was reported as a large abnormal rim enhancing 45 mm 
mass exhibiting a type 4 curve with 120% enhancement.  
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Figure 7: MR data acquired at baseline and post-cycle 2 with respective fits and parameter 
estimates for patient 14 (A) who showed complete pathological response following 7 cycles 
of neoadjuvant chemotherapy (NACT) and patient 17 (B) who showed partial pathological 
response following 6 cycles of NACT.  
 
